Cancer drug developer ChemoCentryx cancels IPO
Mountain View, Calif.-based biotech firm ChemoCentryx announced that it withdrew its filing to go public, citing (as per usual) unfavorable market conditions. The company, which develops drugs to treat cancer and autoimmune ailments like Crohn’s disease, raked in $50 million from its partner GlaxoSmithKline just last month, but the downturn-prompted freeze on IPOs has yet to thaw.
While only four health care companies have been able to go public this year, the company says that the $57.5 million total contributed by GSK is roughly the same amount it hoped to raise through an IPO, reports VentureWire.
GSK and ChemoCentryx first struck the symbiotic deal in 2006, with the former providing a payday of $63.5 million, making it the company’s second largest investor. It has also received capital from Alta Partners, HBM BioVentures and OrbiMed Advisors.
Next Story: Eureka strikes $6M for cancer antibodies
Previous Story: Double down? Spin in? New questions for a new economy
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.